ProteoNic BV
- Biotech or pharma, therapeutic R&D
ProteoNic has introduced its 2G UNic® Transposon platform, now available for licensing. This next-gen gene integration system enables fast, stable, and high-yield expression for cell line development and viral vector production.
It builds on the proven performance of ProteoNic’s 2G UNic® technology, combining efficient integration with strong expression to speed up timelines and reduce COGs.
The transposon platform complements ProteoNic’s widely adopted 2G UNic® vector technology, used to boost production of therapeutic proteins and viral vectors across multiple host systems. Validated in GMP settings and trusted by leading biopharma and CDMOs, the platform supports higher productivity and consistent performance across antibodies, complex biologics, as well as cell and gene therapy applications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}